Ovarian Cancer

Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, advises physicians on considering secondary cytoreductive surgery in ovarian cancer.

PARP inhibitors offer exciting opportunities to improve outcomes for patients with ovarian cancer and hopefully will be moved to the front-line setting if the evidence warrants it, said Susana M. Campos, MD.

There is a great need—and opportunity—to improve ovarian cancer outcomes by understanding the immune milieu of ovarian cancers and harnessing the power of immunotherapy.

Paul Sabbatini, MD, deputy physician-in-chief for clinical research, Memorial Sloan Kettering Cancer Center, discusses the future of dose-dense therapy in ovarian cancer.

Maintenance therapy with olaparib monotherapy provides clinically significant, long-term treatment benefits and is safe in patients with platinum-sensitive relapsed serous ovarian cancer.

Cristiana Sessa, MD, head of Phase I-II Unit and Pharmacology, vice head of Medical Oncology and Head of Clinical Research, Oncology Institute of Southern Switzerland, discusses ataxia–telangiectasia and Rad3 related (ATR) inhibitors in patients with ovarian cancer who have BRCA-mutated tumors.

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses the results of the ARIEL3 trial in ovarian cancer.

Jonathan Ledermann, MD, discussed these results, as well as the future of PARP inhibitors in the maintenance setting for patients with ovarian cancer.

Patients with ovarian cancer were unified in their responses regardless of age, disease stage, or whether they had primary or recurrent disease, and were more likely to opt to receive maintenance therapy if it could offer delay of disease progression and allow patients to maintain or improve their quality of life.

Deleterious mutations in the PALB2 gene may account for the development of breast cancer in women with an elevated risk due to a family history of breast or ovarian cancer, but who test negative for the BRCA1 or BRCA2 genes.

Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the role of surgery for patients with ovarian cancer.

Rucaparib delayed disease recurrence in the intent to treat population and across subgroups of women with ovarian cancer.

Jalid Sehouli, MD, PhD, discusses the significance of these findings in the treatment of patients with platinum-sensitive recurrent ovarian cancer.

The final analysis of overall survival data from the phase III AGO-OVAR 12 trial of nintedanib plus carboplatin/paclitaxel versus carboplatin/paclitaxel alone in women with chemotherapy-naive advanced ovarian cancer did not demonstrate a survival advantage with the addition of nintedanib.

Patients with relapsed ovarian cancer and a positive Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) score experienced prolonged progression-free survival after undergoing a second cytoreductive surgery followed by platinum-based chemotherapy.

Jalid Sehouli, MD, professor, director of the Clinic Campus Virchow and Campus Benjamin Franklin Charité Center Gynecology, Charité – Universitatsmedizin Berlin, discusses a trial of secondary cytoreductive surgery in patients with ovarian cancer, presented at the 2017 International Meeting of the European Society of Gynaecological Oncology (ESGO).

Paul Sabbatini, MD, discusses the recent data surrounding IP and dose-dense therapy and the next steps for both treatment approaches in ovarian cancer.

Mario M. Leitao, Jr, MD, FACOG, FACS, discusses how surgery retains its imperative role in ovarian cancer and sheds light on the challenges that still remain.

Antineoplastic drug therapy has been delivered by the oral route since the earliest days of the modern chemotherapeutic era.

Bhavana Pothuri, MD, an associate professor in the Department of Obstetrics and Gynecology at NYU Langone's Perlmutter Cancer Center, discusses PARP inhibitors for the treatment of patients with ovarian cancer.

The FDA has accepted a supplemental biologics license application for bevacizumab (Avastin) for the first-line treatment of advanced ovarian cancer.

A supplemental new drug application has been submitted to the FDA for rucaparib as maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Peter Dottino, MD, discusses the utilization of molecular methods to identify ovarian cancer following treatment with chemotherapy, and how this type of research impacts the field going forward.